| IXAZOMIB Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Newly Diagnosed Multiple Myeloma (NCT01850524) | Millennium Pharmaceuticals, Inc. | 2013-04-29 |
| Study of Weekly Carfilzomib, Cyclophosphamide and Dexamethasone In Newly Diagnosed Multiple Myeloma Patients (wCCyd) (NCT01857115) | European Myeloma Network B.V. | 2013-04-01 |
| WT1 Vaccine Treatment of Patients With Multiple Myeloma After Autologous Stem Cell Transplantation (NCT01827137) | Sellas Life Sciences Group | 2013-04-01 |
| A Multicenter Phase I Study of MRX34, MicroRNA miR-RX34 Liposomal Injection (NCT01829971) | Mirna Therapeutics, Inc. | 2013-04-01 |
| Study to Evaluate Optimized Retreatment and Prolonged Therapy With Bortezomib (NCT01910987) | Janssen-Cilag International NV | 2013-04-01 |
| Randomized Trial of G-CSF Alone Versus Intermediate-dose Ara-C Plus G-CSF Mobilization in Multiple Myeloma Patients. (NCT01908621) | Maria Sklodowska-Curie National Research Institute of Oncology | 2013-03-20 |
| Monitoring of Deep of Response During Lenalidomide Maintenance in MM Patients Achieving at Least Very Good Partial Response (MRD) (NCT03433365) | Fondazione EMN Italy Onlus | 2013-03-01 |
| Clinical Trial of Expanded and Activated Autologous NK Cells to Treat Multiple Myeloma (NCT02481934) | Joaquín Martínez López, MD, PhD | 2013-03-01 |
| Cyclophosphamide With Biochemical Progression During Lenalidomide-Dexamethasone Treatment for Relapsed/Refractory Multiple Myeloma (MM) (NCT02206503) | Fondazione EMN Italy Onlus | 2013-03-01 |
| Lenalidomide/Bortezomib/Dexamethasone for Multiple Myeloma (MM) (NCT01782963) | Massachusetts General Hospital | 2013-03-01 |
| Acupuncture for Symptom Control in Hematopoietic Stem Cell Transplantation Patients (NCT01811862) | Memorial Sloan Kettering Cancer Center | 2013-03-01 |
| Ex-Vivo Depletion of Myeloma Cells From Peripheral Blood Progenitor Cell Grafts (NCT00968396) | M.D. Anderson Cancer Center | 2013-02-01 |
| Exploration of Immune Response to Early PCV13 Vaccination in Conjunction With Autologous Transplant (NCT01852591) | H. Lee Moffitt Cancer Center and Research Institute | 2013-02-01 |
| Glutamine in Preventing Peripheral Neuropathy in Patients With Multiple Myeloma Receiving Bortezomib (NCT01783522) | Beth Faiman | 2013-02-01 |
| Dovitinib Combined With Bortezomib and Dexamethasone for Relapsed/Refractory Multiple Myeloma (NCT01680796) | University of Florida | 2013-02-01 |
| Bendamustine + Pomalidomide + Dex in R/R Multiple Myeloma (NCT01754402) | Cristina Gasparetto | 2013-01-07 |
| Safety and Efficacy of Pomalidomide, Bortezomib and Low-dose Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma (NCT01734928) | Celgene | 2013-01-07 |
| Evaluation of PET/MR and PET/CT Imaging for Bone Marrow Lesions (NCT01880762) | NYU Langone Health | 2013-01-01 |
| A Safety Study of Carfilzomib, Cyclophosphamide & Dexamethasone Prior to ASCT in Patients With Newly Diagnosed Myeloma (NCT01660750) | Criterium, Inc. | 2013-01-01 |
| Clarithromycin, Sulfamethoxazole/Trimethoprim or Observation in Newly Diagnosed Multiple Myeloma (NCT02624440) | Henrik Gregersen | 2013-01-01 |
| Cancer Stem Cells in Multiple Myeloma (NCT01820546) | Ankara University | 2013-01-01 |
| Busulfan and Melphalan Conditioning in Multiple Myeloma (NCT01923935) | Chonnam National University Hospital | 2013-01-01 |
| First Line Treatment Trial in Multiple Myeloma, Finnish Myeloma Group- Multiple Myeloma 02 (NCT01790737) | Kuopio University Hospital | 2013-01-01 |
| Velcade, Thalidomide, Dexamethasone and Panobinostat Treatment and Panobinostat Maintenance in Multiple Myeloma (NCT02145715) | Prof Jamie Cavenagh | 2013-01-01 |
| A Phase 1 Study Evaluating AMG 232 in Advanced Solid Tumors or Multiple Myeloma (NCT01723020) | Kartos Therapeutics, Inc. | 2012-12-27 |
| Velcade + Cyclophosphamide in Newly Diagnosed Multiple Myeloma (NCT01729338) | Duke University | 2012-12-19 |
| Phase 1 Pharmacokinetic Study of Oral Ixazomib Plus Lenalidomide and Dexamethasone in Adult Asian Participants With Relapsed and/or Refractory Multiple Myeloma (NCT01645930) | Millennium Pharmaceuticals, Inc. | 2012-12-17 |
| A Dose-finding Study of the Bromodomain (Brd) Inhibitor OTX015/ Birabresib (MK-8628) in Hematologic Malignancies (MK-8628-001) (NCT01713582) | Oncoethix GmbH, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | 2012-12-14 |
| Study of Hypotensive Hematopoietic Malignancy Patients' USCOM Readings (NCT01755000) | Washington University School of Medicine | 2012-12-01 |
| Romidepsin in Combination With Lenalidomide in Adults With Relapsed or Refractory Lymphomas and Myeloma (NCT01755975) | Memorial Sloan Kettering Cancer Center | 2012-12-01 |
| Lenalidomide After Allo Transplant (NCT01750762) | Beth Israel Deaconess Medical Center | 2012-12-01 |
| A Study of PAD Followed by Autologous Stem Cell Transplantation (ASCT) to Treat Newly Diagnosed Multiple Myeloma (NCT01852799) | Shanghai Changzheng Hospital | 2012-12-01 |
| Autologous Stem Cell Transplant With Pomalidomide (CC-4047®) Maintenance Versus Continuous Clarithromycin/ Pomalidomide / Dexamethasone Salvage Therapy in Relapsed or Refractory Multiple Myeloma (NCT01745588) | Memorial Sloan Kettering Cancer Center | 2012-12-01 |
| Dose Escalation Trial of WT1-specific Donor-derived T Cells Following T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Relapsed/Refractory Multiple Myeloma (NCT01758328) | Memorial Sloan Kettering Cancer Center | 2012-12-01 |
| Palifermin With Leuprolide Acetate for the Promotion of Immune Recovery Following Total Body Irradiation Based T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation (NCT01746849) | Memorial Sloan Kettering Cancer Center | 2012-12-01 |
| Safety & Efficacy Study High Dose Evomela Injection for MA Conditioning in MM Patients With Autologous Transplantation (NCT01660633) | Acrotech Biopharma Inc. | 2012-12-01 |
| Phase II Study to Evaluate Fenofibrate Therapy in Patients With Smoldering or Symptomatic Multiple Myeloma (NCT01965834) | University of Miami | 2012-11-19 |
| Evaluation of Safety of Pomalidomide in Combination With Dexamethasone (Low Dose) in Patients With Refractory or Relapsed and Refractory Multiple Myeloma (NCT01712789) | Celgene | 2012-11-06 |
| Bone Marrow and Kidney Transplant for Patients With Chronic Kidney Disease and Blood Disorders (NCT01758042) | Massachusetts General Hospital | 2012-11-01 |
| SST0001 (Roneparstat) in Advanced Multiple Myeloma (NCT01764880) | Sigma Tau Research Switzerland SA | 2012-11-01 |
| A Phase 2 Study of Lenalidomide to Evaluate the Efficacy in Japanese Patients With Newly Diagnosed Multiple Myeloma (NCT01698801) | Celgene | 2012-10-01 |
| An Open Label, International, Multi-centre, Phase I/IIa Study of Lenalidomide (Revlimid) and Romidepsin (Istodax) for Relapsed /Refractory Hodgkin Lymphoma, Mature T-cell Lymphoma and Multiple Myeloma. (RId Study) (NCT01742793) | Yale University | 2012-10-01 |
| Diagnostic Imaging of Myeloma Bone Lesions (NCT03147326) | Herlev Hospital | 2012-10-01 |
| A Study to Evaluate the Safety, Pharmacokinetics, and Hematopoietic Stem Cell Mobilization of TG-0054 Alone or in Combination With G-CSF in Patients With Multiple Myeloma, Non-Hodgkin Lymphoma or Hodgkin Disease (NCT01458288) | GPCR Therapeutics, Inc. | 2012-10-01 |
| Expanded Natural Killer (NK) Cells for Multiple Myeloma Study (NCT01040026) | University Hospital, Basel, Switzerland | 2012-10-01 |
| Efficacy of NF-kB Inhibition for Reducing Symptoms During Maintenance Therapy in Multiple Myeloma Patients (NCT01269203) | M.D. Anderson Cancer Center | 2012-10-01 |
| A Study to Assess Renal Function Response to Treatment in Patients With Relapsed Multiple Myeloma and Creatinine Clearance (NCT02849444) | Celgene | 2012-09-23 |
| Tissue Collection for Studies of Lymph Cancer (NCT01676805) | National Cancer Institute (NCI) | 2012-09-21 |
| Open-label Extended Access Program on Lenalidomide Plus Dexamethasone in Chinese Subjects With Relapsed/Refractory Multiple Myeloma Who Participated in CC-5013-MM021 for at Least 1 Year (NCT02348528) | Celgene | 2012-09-11 |
| A Trial of ASP7487 (OSI-906) in Combination With Bortezomib for the Treatment of Relapsed Multiple Myeloma (NCT01672736) | University Health Network, Toronto | 2012-09-01 |
| Phase II Study of V-BEAM Conditioning Regimen Prior to Second Autologous Stem Cell Transplantation (NCT01653418) | Washington University School of Medicine | 2012-09-01 |
| Lenalidomide and Dexamethasone With/Without Stem Cell Transplant in Patients With Multiple Myeloma (NCT01731886) | Columbia University | 2012-09-01 |
| Geriatric Assessments in Senior Adults With Multiple Myeloma (NCT01746030) | Washington University School of Medicine | 2012-09-01 |
| Assessment of Impact Nutritional Program During Autologous Stem Cell Transplant (NCT01699581) | Greg Monohan | 2012-09-01 |
| Lenalidomide Maintenance Therapy for Multiple Myeloma (NCT01675141) | National Cancer Institute (NCI) | 2012-08-20 |
| Carfilzomib, Pomalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma (NCT01665794) | University of Chicago | 2012-08-13 |
| An Investigational Immuno-Therapy Study to Determine the Safety and Effectiveness of Nivolumab and Daratumumab in Patients With Multiple Myeloma (NCT01592370) | Bristol-Myers Squibb | 2012-08-02 |
| Total Marrow Irradiation for Refractory Acute Leukemia (NCT00686556) | Masonic Cancer Center, University of Minnesota | 2012-08-01 |
| Overcoming Chemotherapy Resistance In Refractory Multiple Myeloma With Simvastatin and Zoledronic Acid (NCT01772719) | University of Louisville | 2012-08-01 |
| Total Marrow Irradiation and High-dose Melphalan for Double Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma (NCT01665014) | Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Gliwice | 2012-08-01 |
| Panobinostat Biological Correlates Study (NCT01658241) | Peter MacCallum Cancer Centre, Australia | 2012-07-16 |
| Study of ACY-1215 in Combination With Lenalidomide, and Dexamethasone in Multiple Myeloma (NCT01583283) | Celgene | 2012-07-12 |
| Phase II Study of Subcutaneous (SC) Bortezomib, Lenalidomide and Dexamethasone for Relapsed and/or Refractory Multiple Myeloma; Followed by SC Bortezomib Maintenance (NCT01647165) | National Cancer Institute (NCI) | 2012-07-11 |
| Autophagy Induction After Bortezomib for Myeloma (NCT01594242) | Abramson Cancer Center at Penn Medicine | 2012-07-10 |
| A Study of Weekly Carfilzomib in Combination With Dexamethasone for Progressive Multiple Myeloma (NCT01677858) | Amgen | 2012-07-04 |
| BT062 in Combination With Lenalidomide or Pomalidomide and Dexamethasone in Patients With Multiple Myeloma (NCT01638936) | Biotest Pharmaceuticals Corporation | 2012-07-03 |
| Phase II, Single-Center, Oral Panobinostat in Combination With Lenalidomide and Dexamethasone in Multiple Myeloma (MM) (NCT01651039) | Ajai Chari | 2012-07-01 |
| Phase II Trial Designed to Determine Efficacy and Safety of Bendamustine+Dexamethasone+Thalidomide in R/R MM (NCT01526694) | Azienda Ospedaliera di Bolzano | 2012-07-01 |
| Carfilzomib and Stem Cell Transplant for Plasma Cell Myeloma (NCT01658904) | National Cancer Institute (NCI) | 2012-07-01 |
| A Study of Tabalumab (LY2127399) in Participants With Previously Treated Multiple Myeloma (MM) (NCT01602224) | Eli Lilly and Company | 2012-07-01 |
| Study of Tabalumab (LY2127399) in Japanese Participants With Relapsed or Refactory Multiple Myeloma (NCT01556438) | Eli Lilly and Company | 2012-07-01 |
| Daratumumab in Combination With Lenalidomide and Dexamethasone in Relapsed and Relapsed-refractory Multiple Myeloma (NCT01615029) | Janssen Research & Development, LLC | 2012-06-26 |
| Phase 3 Study With Carfilzomib and Dexamethasone Versus Bortezomib and Dexamethasone for Relapsed Multiple Myeloma Patients (NCT01568866) | Amgen | 2012-06-20 |
| Prospective Research Assessment in Multiple Myeloma: An Observational Evaluation (PREAMBLE) (NCT01838512) | Bristol-Myers Squibb | 2012-06-13 |
| XL184 For Relapsed/Refractory Multiple Myeloma (MM) With Bone Disease (NCT01582295) | Massachusetts General Hospital | 2012-06-01 |
| Filgrastim in Treating Patients With Bortezomib-, Carfilzomib-, or IMID-Refractory Multiple Myeloma (NCT01537861) | Washington University School of Medicine | 2012-06-01 |
| Study of Pomalidomide to Evaluate the Pharmacokinetics and Safety for Patients With Multiple Myeloma and Impaired Renal Function (POM Renal) (NCT01575925) | Celgene | 2012-06-01 |
| Serum Vitamin D Levels and Peripheral Neuropathy Among Multiple Myeloma Patients (NCT01697839) | Oncotherapeutics | 2012-06-01 |
| Carfilzomib, Lenalidomide, and Dexamethasone for Smoldering Multiple Myeloma (NCT01572480) | National Cancer Institute (NCI) | 2012-05-29 |
| Carfilzomib, Pegylated Liposomal Doxorubicin Hydrochloride, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma (NCT01246063) | Washington University School of Medicine | 2012-05-14 |
| Subcutaneous (SC) Bortezomib-Regimens for Patients With RR MM Failing Prior IV Bortezomib-Containing Regimens (NCT01695330) | Oncotherapeutics | 2012-05-01 |
| Carfilzomib + High Dose Melphalan as Preparative Regimen for Autologous Hematopoietic Stem Cell Transplantation (NCT01690143) | University of Alabama at Birmingham | 2012-05-01 |
| Dasatinib for Immune Modulation After Donor Stem Cell Transplant for Hematologic Malignancies (NCT01643603) | Barbara Ann Karmanos Cancer Institute | 2012-05-01 |
| Safety and Pharmacokinetic Profile of CKD-581 (NCT01580371) | Chong Kun Dang Pharmaceutical | 2012-05-01 |
| Tandem Auto Transplantation in Myeloma Patients With <12 Months of Prior Treatment (NCT01548573) | University of Iowa | 2012-05-01 |
| Sotatercept (ACE-011) With Lenalidomide or Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma (NCT01562405) | Massachusetts General Hospital | 2012-05-01 |
| A Study of Oral LGH447 in Patients With Relapsed and/or Refractory Multiple Myeloma (NCT01456689) | Novartis Pharmaceuticals | 2012-04-25 |
| Carfilzomib, Clarithromycin (Biaxin®), Lenalidomide (Revlimid®), and Dexamethasone (Decadron®) [Car-BiRD] Therapy for Subjects With Multiple Myeloma (NCT01559935) | Weill Medical College of Cornell University | 2012-04-19 |
| Validation of a Comprehensive Health Status Assessment Scale in Elderly Patients (≥ 65 Years) With Hematological Malignancies (NCT02164071) | Celgene | 2012-04-11 |
| Allogeneic Transplantation Using Timed Sequential Busulfan and Fludarabine Conditioning (NCT01572662) | M.D. Anderson Cancer Center | 2012-04-11 |
| Eltrombopag for Thrombocytopenia in Patients With Relapsed Multiple Myeloma (NCT01484314) | Dana-Farber Cancer Institute | 2012-04-01 |
| Administration of Tadalafil in Conjunction With Lenalidomide and Dexamethasone in Patients With Multiple Myeloma (NCT01374217) | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 2012-04-01 |
| Clarithromycin Plus CTd Regimen for Patients With Newly Diagnosed Multiple Myeloma (NCT02248428) | Jinling Hospital, China | 2012-04-01 |
| Autologous Stem Cell Transplantation and Maintenance Therapy for Multiple Myeloma (NCT01617213) | University of Virginia | 2012-04-01 |
| Urinary Protein/Creatinine Ratio in a Single Urine Sample Versus 24-hour Proteinuria in Patients With Multiple Myeloma (NCT01572857) | Rennes University Hospital | 2012-04-01 |
| Japanese Phase 1 Study to Evaluate Tolerated Dose, Safety, and Efficacy of Pomalidomide in Patients With Refractory or Relapsed and Refractory Multiple Myeloma (NCT01568294) | Celgene | 2012-04-01 |
| Imaging Studies and the Development of Multiple Myeloma (NCT01571726) | National Cancer Institute (NCI) | 2012-03-27 |
| NOX-A12 in Combination With Bortezomib and Dexamethasone in Relapsed Multiple Myeloma (NCT01521533) | TME Pharma AG | 2012-03-01 |
| Safety, Efficacy and Pharmacokinetic Study of PRLX 93936 in Patients With Multiple Myeloma (NCT01695590) | Prolexys Pharmaceuticals | 2012-03-01 |
| Bendamustine, Lenalidomide (Revlimid®) and Dexamethasone (BRd) as 2nd-line Therapy for Patients With Relapsed or Refractory Multiple Myeloma (NCT01701076) | Cantonal Hospital of St. Gallen | 2012-03-01 |